OTCMKTS:CAPS

Capstone Therapeutics Competitors

$36.01
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.01
Now: $36.01
$36.01
50-Day Range
$34.00
MA: $34.24
$36.01
52-Week Range
$36.01
Now: $36.01
$36.01
VolumeN/A
Average Volume304 shs
Market Capitalization$2.84 million
P/E RatioN/A
Dividend YieldN/A
Beta176.15

Competitors

Capstone Therapeutics (OTCMKTS:CAPS) Vs. TLGT, TOWTF, BETRF, WHCA, PKPH, and ACUR

Should you be buying CAPS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Capstone Therapeutics, including Teligent (TLGT), Tower One Wireless (TOWTF), BetterLife Pharma (BETRF), Williston (WHCA), Peak Pharmaceuticals (PKPH), and Acura Pharmaceuticals (ACUR).

Teligent (NASDAQ:TLGT) and Capstone Therapeutics (OTCMKTS:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Teligent and Capstone Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teligent01002.00
Capstone Therapeutics0000N/A

Teligent currently has a consensus price target of $2.00, suggesting a potential upside of 284.84%. Given Teligent's higher possible upside, equities analysts clearly believe Teligent is more favorable than Capstone Therapeutics.

Insider & Institutional Ownership

28.2% of Teligent shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 2.1% of Teligent shares are owned by insiders. Comparatively, 42.8% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Teligent and Capstone Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teligent-91.50%N/A-17.52%
Capstone TherapeuticsN/AN/AN/A

Volatility & Risk

Teligent has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of 176.15, suggesting that its stock price is 17,515% more volatile than the S&P 500.

Earnings and Valuation

This table compares Teligent and Capstone Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teligent$65.90 million0.17$-25,120,000.00N/AN/A
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A

Capstone Therapeutics has lower revenue, but higher earnings than Teligent.

Summary

Capstone Therapeutics beats Teligent on 6 of the 9 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Tower One Wireless (OTCMKTS:TOWTF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are held by institutional investors. 42.8% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Capstone Therapeutics has a beta of 176.15, indicating that its share price is 17,515% more volatile than the S&P 500. Comparatively, Tower One Wireless has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Capstone Therapeutics and Tower One Wireless, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Tower One Wireless0000N/A

Earnings & Valuation

This table compares Capstone Therapeutics and Tower One Wireless' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A
Tower One Wireless$4.08 million2.56$-3,750,000.00N/AN/A

Capstone Therapeutics has higher earnings, but lower revenue than Tower One Wireless.

Profitability

This table compares Capstone Therapeutics and Tower One Wireless' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
Tower One WirelessN/AN/A-39.36%

Summary

Capstone Therapeutics beats Tower One Wireless on 5 of the 7 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and BetterLife Pharma (OTCMKTS:BETRF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Capstone Therapeutics and BetterLife Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
BetterLife Pharma0000N/A

Valuation & Earnings

This table compares Capstone Therapeutics and BetterLife Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A

Capstone Therapeutics has higher revenue and earnings than BetterLife Pharma.

Profitability

This table compares Capstone Therapeutics and BetterLife Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
BetterLife PharmaN/A-734.15%-219.66%

Volatility & Risk

Capstone Therapeutics has a beta of 176.15, meaning that its share price is 17,515% more volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 3.8, meaning that its share price is 280% more volatile than the S&P 500.

Insider and Institutional Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Capstone Therapeutics beats BetterLife Pharma on 7 of the 7 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares Capstone Therapeutics and Williston's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
WillistonN/AN/AN/A

Risk & Volatility

Capstone Therapeutics has a beta of 176.15, suggesting that its stock price is 17,515% more volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500.

Earnings & Valuation

This table compares Capstone Therapeutics and Williston's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A
WillistonN/AN/AN/AN/AN/A

Williston has lower revenue, but higher earnings than Capstone Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Capstone Therapeutics and Williston, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Williston0000N/A

Insider and Institutional Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Capstone Therapeutics beats Williston on 4 of the 4 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are held by institutional investors. 42.8% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Capstone Therapeutics has a beta of 176.15, meaning that its share price is 17,515% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares Capstone Therapeutics and Peak Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Peak Pharmaceuticals has lower revenue, but higher earnings than Capstone Therapeutics.

Profitability

This table compares Capstone Therapeutics and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
Peak PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Capstone Therapeutics and Peak Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Peak Pharmaceuticals0000N/A

Summary

Capstone Therapeutics beats Peak Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Acura Pharmaceuticals (OTCMKTS:ACUR) and Capstone Therapeutics (OTCMKTS:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares Acura Pharmaceuticals and Capstone Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acura Pharmaceuticals$2.66 million3.36N/AN/AN/A
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A

Acura Pharmaceuticals has higher revenue and earnings than Capstone Therapeutics.

Analyst Ratings

This is a breakdown of current recommendations for Acura Pharmaceuticals and Capstone Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acura Pharmaceuticals0000N/A
Capstone Therapeutics0000N/A

Risk & Volatility

Acura Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of 176.15, indicating that its stock price is 17,515% more volatile than the S&P 500.

Insider and Institutional Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 5.6% of Acura Pharmaceuticals shares are owned by company insiders. Comparatively, 42.8% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Acura Pharmaceuticals and Capstone Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acura Pharmaceuticals-19.89%-1.36%-34.83%
Capstone TherapeuticsN/AN/AN/A

Summary

Capstone Therapeutics beats Acura Pharmaceuticals on 6 of the 8 factors compared between the two stocks.


Capstone Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Teligent logo
TLGT
Teligent
1.2$0.52flat$11.31 million$65.90 million-0.06
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.11flat$10.86 million$4.08 million-1.24Gap Up
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.56flat$10.84 millionN/A-0.74
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.11flat$9.25 millionN/A0.00News Coverage
Gap Up
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.40flat$8.93 million$2.66 million-13.47Gap Up
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.38flat$8.51 millionN/A0.00Gap Up
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.17flat$7.32 millionN/A0.00News Coverage
Gap Down
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.37flat$7.20 millionN/A0.00Gap Down
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.07flat$6.39 millionN/A0.00Gap Up
KAYS
Kaya
0.7$0.44flat$6.38 million$1.01 million0.00
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.04flat$5.71 million$30,000.000.00
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.19flat$4.81 million$3.48 million-1.59Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.63flat$4.07 million$9.47 million0.00High Trading Volume
Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09flat$3.75 million$3.65 million0.00News Coverage
Gap Up
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01flat$3.63 millionN/A0.00
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.36 millionN/A0.00Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.82 millionN/A-0.09News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45flat$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.83 millionN/A0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.78 million$530,000.000.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$1.70 million$20,000.00-0.79Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50flat$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95flat$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26flat$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90flat$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21flat$1.17 millionN/A0.00Decrease in Short Interest
Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25flat$1.12 millionN/A-2.76Upcoming Earnings
Gap Down
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$991,000.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$978,000.00N/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.06flat$872,000.00$250,000.000.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$865,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00flat$763,000.00N/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.02flat$693,000.00N/A0.00Gap Up
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$547,000.00N/A0.00Gap Down
TRPXD
Therapix Biosciences
0.0$9.20flat$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.16flat$399,000.00N/A0.00Gap Up
SKVI
Skinvisible
0.7$0.10flat$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$366,000.00N/A0.00Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.